Table 1.
Clinical Characteristics of the Sample Set According to IDH Mutation and 1p/19q Codeletion Status.*
| Characteristic | Total (N = 278)† | IDH Mutation and 1p/19q Codeletion (N = 84) | IDH Mutation and No 1p/19q Codeletion(N = 139) | IDH Wild Type(N = 55) |
|---|---|---|---|---|
| Histologic type‡ and grade‡ — no. (%) | ||||
| Oligodendroglioma | ||||
| Grade II | 65 (23) | 38 (45) | 21 (15) | 6 (11) |
| Grade III | 44 (16) | 31 (37) | 6 (4) | 7 (13) |
| Oligoastrocytoma | ||||
| Grade II | 41 (15) | 9 (11) | 30 (22) | 2 (4) |
| Grade III | 33 (12) | 4 (5) | 20 (14) | 9 (16) |
| Astrocytoma | ||||
| Grade II | 30 (11) | 1 (1) | 24 (17) | 5 (9) |
| Grade III | 65 (23) | 1 (1) | 38 (27) | 26 (47) |
| Age at diagnosis — yr‡ | ||||
| Mean | 42.6±13.5 | 45.4±13.2 | 38.1±10.9 | 49.9±15.3 |
| Range | 14–75 | 17–75 | 14–70 | 21–74 |
| Male sex — no. (%) | 155 (56) | 45 (54) | 84 (60) | 26 (47) |
| White race — no./total no. (%)§ | 261/274 (95) | 79/81 (98) | 131/138 (95) | 51/55 (93) |
| Year of diagnosis — no. (%) | ||||
| Before 2005 | 38 (14) | 10 (12) | 18 (13) | 10 (18) |
| 2005–2009 | 88 (32) | 30 (36) | 44 (32) | 14 (25) |
| 2010–2013 | 152 (55) | 44 (52) | 77 (55) | 31 (56) |
| Family history of cancer — no./total no. (%)¶ | ||||
| None | 108/190 (57) | 30/58 (52) | 64/98 (65) | 13/34 (38) |
| Primary brain cancer | 11/190 (6) | 2/58 (3) | 7/98 (7) | 2/34 (6) |
| Other cancers | 72/190 (38) | 26/58 (45) | 27/98 (28) | 19/34 (56) |
| Extent of resection — no./total no. (%) | ||||
| Open biopsy | 6/268 (2) | 1/81 (1) | 4/132 (3) | 1/55 (2) |
| Subtotal resection | 98/268 (37) | 31/81 (38) | 45/132 (34) | 22/55 (40) |
| Gross total resection | 164/268 (61) | 49/81 (60) | 83/132 (63) | 32/55 (58) |
| Tumor location — no. (%)‡ | ||||
| Frontal lobe | 172 (62) | 68 (81) | 84 (60) | 20 (36) |
| Parietal lobe | 23 (8) | 5 (6) | 13 (9) | 5 (9) |
| Temporal lobe | 74 (27) | 9 (11) | 40 (29) | 25 (45) |
| Other || | 9 (3) | 2 (2) | 2 (1) | 5 (9) |
| Laterality — no./total no. (%) | ||||
| Left | 133/276 (48) | 37/84 (44) | 69/137 (50) | 27/55 (49) |
| Midline | 5/276 (2) | 2/84 (2) | 2/137 (1) | 1/55 (2) |
| Right | 138/276 (50) | 45/84 (54) | 66/137 (48) | 27/55 (49) |
| White matter — no./total no. (%) | 74/144 (51) | 26/48 (54) | 37/72 (51) | 11/24 (46) |
| First presenting symptom — no./total no. (%) | ||||
| Headache | 64/252 (25) | 15/72 (21) | 39/129 (30) | 10/51 (20) |
| Mental status change | 22/252 (9) | 7/72 (10) | 10/129 (8) | 5/51 (10) |
| Motor or movement change | 18/252 (7) | 6/72 (8) | 7/129 (5) | 5/51 (10) |
| Seizure | 135/252 (54) | 38/72 (53) | 70/129 (54) | 27/51 (53) |
| Sensory or visual change | 13/252 (5) | 6/72 (8) | 3/129 (2) | 4/51 (8) |
Plus–minus values are means ±SD. Categorical distributions were compared with the use of Fisher’s exact test. Analysis of variance was used to compare age between groups.
IDH–1p/19q status was not determined for 11 cases with clinical information.
P<0.01 for the difference among the molecular subtypes.
Race was self-reported. Of the 261 patients who reported their ethnic background, 5% identified themselves as Hispanic or Latino.
Included are patients for whom responses to questions regarding a family history of any cancer (192 patients) and a family history of primary brain cancer (197 patients) were available. P<0.05 for the difference among the molecular subtypes.
One case (with wild-type IDH) was in the cerebellum, three cases were in the occipital lobe (two with IDH mutation and 1p/19q codeletion and one with an IDH mutation and no codeletion), and five cases were listed as “supratentorial, not otherwise specified” (one with an IDH mutation and no codeletion and four with wild-type IDH).